Research programme: HIV infection therapeutics - ViroChem Pharma

Drug Profile

Research programme: HIV infection therapeutics - ViroChem Pharma

Alternative Names: CCR5 receptor antagonists - ViroChem Pharma; HIV maturation inhibitors - ViroChem Pharma

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator ViroChem Pharma
  • Developer Vertex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors; Nucleocapsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 12 Mar 2009 ViroChem Pharma has been acquired and merged into Vertex Pharmaceuticals
  • 12 Mar 2009 ViroChem Pharma has been acquired by Vertex Pharmaceuticals
  • 12 Feb 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top